Search results for " type 2"

showing 10 items of 761 documents

Peripheral blood levels of CXCL10 are a useful marker for diabetic polyneuropathy in subjects with type 2 diabetes.

2020

BACKGROUND Diabetic peripheral neuropathy (DPN) is a chronic complication of diabetes mellitus associated with high morbidity and mortality. Major risk factors for DPN include metabolic changes, duration of diabetes, nerve ischaemia and derangements in regeneration and nerve repair programmes. Chemokines have been previously implicated in the pathogenesis of various neuropathies and neuropathic pain processes. The aim of this pilot study was to evaluate the association between the plasma levels of chemokines (CXCL9, CXCL10 and CXCL11) in the presence of DPN in a cohort of type 2 diabetes (T2D) patients. MATERIALS AND METHODS We studied 73 patients with T2D: 36 with DPN and 37 without DPN. D…

medicine.medical_specialtybusiness.industryPilot ProjectsGeneral MedicineType 2 diabetesmedicine.diseaseGastroenterologyChemokine CXCL10Peripheral neuropathyDiabetes Mellitus Type 2Diabetic NeuropathiesRisk FactorsInternal medicineDiabetes mellitusNeuropathic painmedicineCXCL10CXCL9HumansCXCL11ComplicationbusinessBiomarkersInternational journal of clinical practiceREFERENCES
researchProduct

Prädiktive genetische Untersuchungen: Individualisierung von Diagnostik und Therapie bei Familien mit multipler endokriner Neoplasie Typ II

2008

BACKGROUND AND OBJECTIVE When multiple endocrine neoplasia type 2 (MEN2) is suspected, genetic tests are at the centre of screening procedures. It was the aim of this study to compare the diagnostic value of molecular biological investigations with that of conventional biochemical tests. PATIENTS AND METHODS The study cohort consisted of all 144 patients cared for in our department since 1990 with the suspected diagnosis of MEN2 (evidence of a medullary thyroid carcinoma [MTC]), coexistence of two MEN2 tumours or a family history of MEN2. 14 of the 144 patients (from 12 families) were already known to have an hereditary MTC, while the remaining 130 had been referred for further diagnostic i…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentThyroidectomyMultiple endocrine neoplasia type 2General MedicineHyperplasiamedicine.diseaseGastroenterologyThyroid carcinomaCalcitoninInternal medicineCohortmedicineFamily historybusinessScreening proceduresDMW - Deutsche Medizinische Wochenschrift
researchProduct

Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the …

2010

Women with polycystic ovary syndrome (PCOS) often have cardiovascular disease (CVD) risk factors. The Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society created a panel to provide evidence-based reviews of studies assessing PCOS-CVD risk relationships and to develop guidelines for preventing CVD.An expert panel in PCOS and CVD reviewed literature and presented recommendations.Only studies comparing PCOS with control patients were included. All electronic databases were searched; reviews included individual studies/databases, systematic reviews, abstracts, and expert data. Articles were excluded if other hyperandrogenic disorders were not excluded, PCOS diagnosis was unclear, co…

medicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismClinical BiochemistryMEDLINEDiseaseAndrogen ExcessRisk AssessmentBiochemistryBody Mass IndexEndocrinologyRisk FactorsDiabetes mellitusInternal medicineGlucose IntoleranceHumansMedicineWaist-Hip Ratiobusiness.industryBiochemistry (medical)nutritional and metabolic diseasesAtherosclerosismedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsEndocrinologySystematic reviewDiabetes Mellitus Type 2Cardiovascular DiseasesFemaleRisk assessmentbusinessBody mass indexPolycystic Ovary SyndromeThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Insulin resistance and polycystic ovary syndrome.

2008

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in humans, affecting approximately 7-8% of women of reproductive age. Despite the criteria adopted, PCOS is considered to be a predominantly hyperandrogenetic syndrome and the evaluation of metabolic parameters and insulin sensitivity is not mandatory. Most women with PCOS also exhibit features of the metabolic syndrome, including insulin resistance, obesity and dyslipidaemia. While the association with type 2 diabetes is well established, whether the incidence of cardiovascular disease is increased in women with PCOS remains unclear. Acknowledging the strong impact of insulin-resistance in the genesis of PCOS co…

medicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Type 2 diabetesDiseaseEnvironmentBioinformaticsSettore MED/13 - EndocrinologiaInsulin resistanceRisk FactorsDiabetes mellitusInternal medicinemedicineHumansHypoglycemic AgentsGenetic Predisposition to DiseaseNutrition and Dieteticsbusiness.industryIncidenceHyperandrogenismnutritional and metabolic diseasesmedicine.diseasePolycystic ovaryObesityfemale genital diseases and pregnancy complicationsEndocrinologyDiabetes Mellitus Type 2Cardiovascular DiseasesFemaleInsulin resistance pcosMetabolic syndromeInsulin ResistanceCardiology and Cardiovascular MedicinebusinessPolycystic Ovary SyndromeNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Impact of Non-Alcoholic Fatty Liver Disease on Metabolic Comorbidities in Type 2 Diabetes Mellitus.

2021

Abstract Objective Type 2 Diabetes (T2D) is a major risk factor for the development and progression of non-alcoholic fatty liver disease (NAFLD). The published prevelance in epidemiological studies in this high risk population exceeds 70%. The aim of this analysis was to investigate the impact of NAFLD on T2D patients in Germany. Methods Using the Disease Analyzer Database (IQVIA), T2D patients with NAFLD diagnosed in Germany were matched to a cohort without NAFLD controlling for age, sex, physician, index year and metabolic comorbidities and assessed for their risk of developing myocardial infarction, stroke, peripheral arterial disease (PAD) or chronic kidney disease, as well as the type …

medicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismPopulationType 2 diabetesComorbidity03 medical and health sciencesLiver disease0302 clinical medicineEndocrinologyNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineEpidemiologyInternal MedicinemedicineHumansInsulinRisk factoreducationeducation.field_of_studybusiness.industryFatty livernutritional and metabolic diseasesType 2 Diabetes MellitusGeneral Medicinemedicine.diseasedigestive system diseasesDiabetes Mellitus Type 2030220 oncology & carcinogenesis030211 gastroenterology & hepatologybusinessKidney diseaseExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct

American Association Of Clinical Endocrinologists, American College Of Endocrinology, And Androgen Excess And Pcos Society Disease State Clinical Rev…

2015

Polycystic Ovary Syndrome (PCOS) is recognized as the most common endocrine disorder of reproductive-aged women around the world. This document, produced by the collaboration of the American Association of Clinical Endocrinologists (AACE) and the Androgen Excess and PCOS Society (AES) aims to highlight the most important clinical issues confronting physicians and their patients with PCOS. It is a summary of current best practices in 2015. PCOS has been defined using various criteria, including menstrual irregularity, hyperandrogenism, and polycystic ovary morphology (PCOM). General agreement exists among specialty society guidelines that the diagnosis of PCOS must be based on the presence o…

medicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismType 2 diabetesAndrogen ExcessSeverity of Illness IndexLipoprotein particleFlutamideAnovulationImpaired glucose tolerancechemistry.chemical_compoundEndocrinologyInsulin resistancePregnancyInternal medicinemedicineHumansLife StylehirsutismMetabolic Syndromebusiness.industryHyperandrogenismnutritional and metabolic diseasesGeneral Medicinemedicine.diseasePolycystic ovaryPolycystic ovarian diseaseGestational diabetesEndocrinologyDiabetes Mellitus Type 2chemistryDisease ProgressionSpironolactoneFemaleInsulin ResistanceMetabolic syndromeHyperandrogenismbusinessInfertility FemaleAlgorithmsPolycystic Ovary SyndromeEndocrine Practice
researchProduct

Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.

1994

We have analysed 118 families with inherited medullary thyroid carcinoma (MTC) for mutations of the RET proto-oncogene. These included cases of multiple endocrine neoplasia types 2A (MEN 2A) and 2B (MEN 2B) and familial MTC (FMTC). Mutations at one of 5 cysteines in the extracellular domain were found in 97% of patients with MEN 2A and 86% with FMTC but not in MEN 2B patients or normal controls. 84% of the MEN2A mutations affected codon 634. MEN 2A patients with a Cys634 to Arg substitution had a greater risk of developing parathyroid disease than those with other codon 634 mutations. Our data show a strong correlation between disease phenotype and the nature and position of the RET mutatio…

medicine.medical_specialtyendocrine system diseasesOncogene RETDNA Mutational AnalysisMolecular Sequence DataMultiple endocrine neoplasia type 2RET proto-oncogeneBiologymedicine.disease_causeProto-Oncogene MasInternal medicineProto-Oncogene ProteinsProto-OncogenesGeneticsmedicineDrosophila ProteinsHumansPoint MutationThyroid NeoplasmsMultiple endocrine neoplasiaDNA PrimersMutationBase SequencePoint mutationMultiple Endocrine NeoplasiaProto-Oncogene Proteins c-retReceptor Protein-Tyrosine KinasesExonsmedicine.diseasePhenotypeEndocrinologyPhenotypeProto-Oncogene Proteins c-retCarcinoma MedullaryCancer researchNature genetics
researchProduct

Gestational diabetes and the metabolic syndrome: Can obesity and small, dense low density lipoproteins be key mediators of this association?

2013

Gestational diabetes mellitus (GDM) represents a condition of glucose intolerance with first appearance or recognition at the time of a pregnancy, associated with an inadequate pancreatic response to the advanced insulin resistance of the later stages of pregnancy, and accompanied by enhancing β-cell mass and secretion of insulin. Women who had GDM exhibit a higher risk for later advent of type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD). Additionally, previous GDM has been proposed as independently correlated with higher risk for development of atherosclerosis in a healthy population, similar to the metabolic syndrome (MetS) and independently of the presence of established…

medicine.medical_specialtyendocrine system diseasesPharmaceutical ScienceInsulin resistancePregnancyDiabetes mellitusInternal medicineHumansMedicineObesityMetabolic SyndromePregnancybusiness.industryObstetricsnutritional and metabolic diseasesType 2 Diabetes Mellitusmedicine.diseaseObesityLipoproteins LDLGestational diabetesDiabetes GestationalEndocrinologyFemaleMetabolic syndromecardiovascular disease cardiovascular risk gestational diabetes mellitus metabolic syndrome small dense low-density lipoprotein type 2 diabetes mellitusbusinessPostpartum periodBiotechnology
researchProduct

Regulated Proteolysis of RAGE and AβPP as Possible Link Between Type 2 Diabetes Mellitus and Alzheimer's Disease

2009

Epidemiological studies have linked type 2 diabetes mellitus (T2DM) with an increased risk of developing Alzheimer's disease (AD). In T2DM, the elevated blood glucose level promotes formation of advanced glycation end products (AGEs). The receptor for AGEs (RAGE) is a type I membrane-protein and is also able to import amyloid-beta (Abeta) from the blood across the blood-brain-barrier into the brain. Oligomeric Abeta peptides disturb synaptic function in the brain and are believed to contribute to the development of AD. Abeta peptides are released from the amyloid-beta protein precursor (AbetaPP) after sequential proteolysis by beta- and gamma-secretases but alpha-secretase-mediated cleavage…

medicine.medical_specialtyendocrine system diseasesProteolysisReceptor for Advanced Glycation End ProductsAmyloid beta-Protein PrecursorAlzheimer DiseaseGlycationInternal medicinemental disordersmedicineAnimalsHumansReceptors ImmunologicProtein precursorProtein kinase AReceptorAmyloid beta-Peptidesmedicine.diagnostic_testChemistryGeneral Neurosciencenutritional and metabolic diseasesGeneral MedicinePsychiatry and Mental healthClinical PsychologyCholesterolEndocrinologyDiabetes Mellitus Type 2EctodomainPeptide transportAmyloid Precursor Protein SecretasesGeriatrics and GerontologySignal transductionJournal of Alzheimer's Disease
researchProduct

Effects of empagliflozin on CA125 trajectory in patients with chronic congestive heart failure

2021

INTRODUCTION: We aimed to evaluate the trajectory of two surrogates of fluid overload -antigen carbohydrate 125 (CA125) and amino-terminal pro-brain natriuretic peptide (NT-proBNP)- after the addition of oral empagliflozin to usual care in a cohort of patients with chronic heart failure (CHF) and type 2 diabetes (T2D). METHODS AND RESULTS: From October 2015 to February 2019, 60 ambulatory patients with CHF and T2D were retrospectively included. The primary endpoint was to assess the longitudinal trajectory of plasma levels of CA125 and NT-proBNP after empagliflozin initiation. Changes in quantitative variables were evaluated using linear mixed regression. Median CA125 and NT-proBNP at basel…

medicine.medical_specialtyendocrine system diseasesType 2 diabetes030204 cardiovascular system & hematologyCA12503 medical and health sciences0302 clinical medicineGlucosidesEmplagliflozinInterquartile rangeLongitudinal trajectoriesInternal medicineNatriuretic Peptide BrainmedicineEmpagliflozinClinical endpointHumansSGLT2icardiovascular diseases030212 general & internal medicineBenzhydryl CompoundsRetrospective StudiesHeart FailureSurrogate endpointbusiness.industrymedicine.diseasePeptide FragmentsDiabetes Mellitus Type 2Heart failureNTproBNPAmbulatoryCohortCardiologyCardiology and Cardiovascular MedicinebusinessBiomarkersInternational Journal of Cardiology
researchProduct